Completed PHASE2 INTERVENTIONAL 2-arm NCT00441298

Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa

Sponsor: CONRAD

Conditions HIV Infections

Interventions Placebo (Universal HEC placebo) Tenofovir gel

Updated 5 times since 2017 Last updated: Jan 29, 2016 Started: May 31, 2007 Primary completion: Dec 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by CONRAD and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONRAD
Centre for the AIDS Programme of Research in South Africa
FHI 360
United States Agency for International Development (USAID)

Data source: Centre for the AIDS Programme of Research in South Africa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durban, South Africa
• Pietermaritzburg, South Africa